img

Global Anti-Obesity Prescription Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Obesity Prescription Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
The global Anti-Obesity Prescription Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Anti-Obesity Prescription Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Anti-Obesity Prescription Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Anti-Obesity Prescription Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Anti-Obesity Prescription Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Anti-Obesity Prescription Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
By Type
Pediatric
Adult
By Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Anti-Obesity Prescription Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Prescription Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Anti-Obesity Prescription Drugs Definition
1.2 Market by Type
1.2.1 Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Pediatric
1.2.3 Adult
1.3 Market Segment by Application
1.3.1 Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 E-commerce
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Obesity Prescription Drugs Sales
2.1 Global Anti-Obesity Prescription Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Obesity Prescription Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Anti-Obesity Prescription Drugs Revenue by Region
2.3.1 Global Anti-Obesity Prescription Drugs Revenue by Region (2018-2024)
2.3.2 Global Anti-Obesity Prescription Drugs Revenue by Region (2024-2034)
2.4 Global Anti-Obesity Prescription Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Obesity Prescription Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Anti-Obesity Prescription Drugs Sales Quantity by Region
2.6.1 Global Anti-Obesity Prescription Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Anti-Obesity Prescription Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Obesity Prescription Drugs Sales Quantity by Manufacturers
3.1.1 Global Anti-Obesity Prescription Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Anti-Obesity Prescription Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Obesity Prescription Drugs Sales in 2022
3.2 Global Anti-Obesity Prescription Drugs Revenue by Manufacturers
3.2.1 Global Anti-Obesity Prescription Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-Obesity Prescription Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Obesity Prescription Drugs Revenue in 2022
3.3 Global Anti-Obesity Prescription Drugs Sales Price by Manufacturers
3.4 Global Key Players of Anti-Obesity Prescription Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Obesity Prescription Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Obesity Prescription Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Obesity Prescription Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Obesity Prescription Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Obesity Prescription Drugs Sales Quantity by Type
4.1.1 Global Anti-Obesity Prescription Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Anti-Obesity Prescription Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Obesity Prescription Drugs Revenue by Type
4.2.1 Global Anti-Obesity Prescription Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-Obesity Prescription Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Obesity Prescription Drugs Price by Type
4.3.1 Global Anti-Obesity Prescription Drugs Price by Type (2018-2024)
4.3.2 Global Anti-Obesity Prescription Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Obesity Prescription Drugs Sales Quantity by Application
5.1.1 Global Anti-Obesity Prescription Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Anti-Obesity Prescription Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Obesity Prescription Drugs Revenue by Application
5.2.1 Global Anti-Obesity Prescription Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-Obesity Prescription Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Obesity Prescription Drugs Price by Application
5.3.1 Global Anti-Obesity Prescription Drugs Price by Application (2018-2024)
5.3.2 Global Anti-Obesity Prescription Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Obesity Prescription Drugs Sales by Company
6.1.1 North America Anti-Obesity Prescription Drugs Revenue by Company (2018-2024)
6.1.2 North America Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024)
6.2 North America Anti-Obesity Prescription Drugs Market Size by Type
6.2.1 North America Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Obesity Prescription Drugs Revenue by Type (2018-2034)
6.3 North America Anti-Obesity Prescription Drugs Market Size by Application
6.3.1 North America Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Obesity Prescription Drugs Revenue by Application (2018-2034)
6.4 North America Anti-Obesity Prescription Drugs Market Size by Country
6.4.1 North America Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Anti-Obesity Prescription Drugs Revenue by Country (2018-2034)
6.4.3 North America Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Obesity Prescription Drugs Sales by Company
7.1.1 Europe Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Anti-Obesity Prescription Drugs Revenue by Company (2018-2024)
7.2 Europe Anti-Obesity Prescription Drugs Market Size by Type
7.2.1 Europe Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Obesity Prescription Drugs Revenue by Type (2018-2034)
7.3 Europe Anti-Obesity Prescription Drugs Market Size by Application
7.3.1 Europe Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Obesity Prescription Drugs Revenue by Application (2018-2034)
7.4 Europe Anti-Obesity Prescription Drugs Market Size by Country
7.4.1 Europe Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Anti-Obesity Prescription Drugs Revenue by Country (2018-2034)
7.4.3 Europe Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Obesity Prescription Drugs Sales by Company
8.1.1 China Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Anti-Obesity Prescription Drugs Revenue by Company (2018-2024)
8.2 China Anti-Obesity Prescription Drugs Market Size by Type
8.2.1 China Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Obesity Prescription Drugs Revenue by Type (2018-2034)
8.3 China Anti-Obesity Prescription Drugs Market Size by Application
8.3.1 China Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Obesity Prescription Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Obesity Prescription Drugs Sales by Company
9.1.1 APAC Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Anti-Obesity Prescription Drugs Revenue by Company (2018-2024)
9.2 APAC Anti-Obesity Prescription Drugs Market Size by Type
9.2.1 APAC Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Obesity Prescription Drugs Revenue by Type (2018-2034)
9.3 APAC Anti-Obesity Prescription Drugs Market Size by Application
9.3.1 APAC Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Obesity Prescription Drugs Revenue by Application (2018-2034)
9.4 APAC Anti-Obesity Prescription Drugs Market Size by Region
9.4.1 APAC Anti-Obesity Prescription Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Anti-Obesity Prescription Drugs Revenue by Region (2018-2034)
9.4.3 APAC Anti-Obesity Prescription Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 F Hoffmann La Roche Ltd
11.1.1 F Hoffmann La Roche Ltd Company Information
11.1.2 F Hoffmann La Roche Ltd Overview
11.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Products and Services
11.1.5 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs SWOT Analysis
11.1.6 F Hoffmann La Roche Ltd Recent Developments
11.2 Orexigen Therapeutics
11.2.1 Orexigen Therapeutics Company Information
11.2.2 Orexigen Therapeutics Overview
11.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Products and Services
11.2.5 Orexigen Therapeutics Anti-Obesity Prescription Drugs SWOT Analysis
11.2.6 Orexigen Therapeutics Recent Developments
11.3 Novo Nordisk A/s
11.3.1 Novo Nordisk A/s Company Information
11.3.2 Novo Nordisk A/s Overview
11.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Products and Services
11.3.5 Novo Nordisk A/s Anti-Obesity Prescription Drugs SWOT Analysis
11.3.6 Novo Nordisk A/s Recent Developments
11.4 Arena Pharmaceuticals
11.4.1 Arena Pharmaceuticals Company Information
11.4.2 Arena Pharmaceuticals Overview
11.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Products and Services
11.4.5 Arena Pharmaceuticals Anti-Obesity Prescription Drugs SWOT Analysis
11.4.6 Arena Pharmaceuticals Recent Developments
11.5 Glaxosmithkline
11.5.1 Glaxosmithkline Company Information
11.5.2 Glaxosmithkline Overview
11.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Glaxosmithkline Anti-Obesity Prescription Drugs Products and Services
11.5.5 Glaxosmithkline Anti-Obesity Prescription Drugs SWOT Analysis
11.5.6 Glaxosmithkline Recent Developments
11.6 Vivus
11.6.1 Vivus Company Information
11.6.2 Vivus Overview
11.6.3 Vivus Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Vivus Anti-Obesity Prescription Drugs Products and Services
11.6.5 Vivus Anti-Obesity Prescription Drugs SWOT Analysis
11.6.6 Vivus Recent Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Overview
11.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Products and Services
11.7.5 Boehringer Ingelheim Anti-Obesity Prescription Drugs SWOT Analysis
11.7.6 Boehringer Ingelheim Recent Developments
11.8 Alizyme
11.8.1 Alizyme Company Information
11.8.2 Alizyme Overview
11.8.3 Alizyme Anti-Obesity Prescription Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Alizyme Anti-Obesity Prescription Drugs Products and Services
11.8.5 Alizyme Anti-Obesity Prescription Drugs SWOT Analysis
11.8.6 Alizyme Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Obesity Prescription Drugs Value Chain Analysis
12.2 Anti-Obesity Prescription Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Obesity Prescription Drugs Production Mode & Process
12.4 Anti-Obesity Prescription Drugs Sales and Marketing
12.4.1 Anti-Obesity Prescription Drugs Sales Channels
12.4.2 Anti-Obesity Prescription Drugs Distributors
12.5 Anti-Obesity Prescription Drugs Customers
13 Market Dynamics
13.1 Anti-Obesity Prescription Drugs Industry Trends
13.2 Anti-Obesity Prescription Drugs Market Drivers
13.3 Anti-Obesity Prescription Drugs Market Challenges
13.4 Anti-Obesity Prescription Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Pediatric
Table 3. Major Manufacturers of Adult
Table 4. Global Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Anti-Obesity Prescription Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Anti-Obesity Prescription Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2018-2024)
Table 8. Global Anti-Obesity Prescription Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2024-2034)
Table 10. Global Anti-Obesity Prescription Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Anti-Obesity Prescription Drugs Sales by Region (2018-2024) & (K Units)
Table 12. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2018-2024)
Table 13. Global Anti-Obesity Prescription Drugs Sales by Region (2024-2034) & (K Units)
Table 14. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2024-2034)
Table 15. Global Anti-Obesity Prescription Drugs Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Anti-Obesity Prescription Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Anti-Obesity Prescription Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Anti-Obesity Prescription Drugs Revenue Share by Manufacturers (2018-2024)
Table 19. Global Anti-Obesity Prescription Drugs Price by Manufacturers 2018-2024 (US$/Unit)
Table 20. Global Key Players of Anti-Obesity Prescription Drugs, Industry Ranking, 2021 VS 2022
Table 21. Global Anti-Obesity Prescription Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Anti-Obesity Prescription Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Prescription Drugs as of 2022)
Table 23. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Product Offered and Application
Table 25. Global Key Manufacturers of Anti-Obesity Prescription Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Anti-Obesity Prescription Drugs Sales Quantity Share by Type (2018-2024)
Table 30. Global Anti-Obesity Prescription Drugs Sales Quantity Share by Type (2024-2034)
Table 31. Global Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Anti-Obesity Prescription Drugs Revenue Share by Type (2018-2024)
Table 34. Global Anti-Obesity Prescription Drugs Revenue Share by Type (2024-2034)
Table 35. Anti-Obesity Prescription Drugs Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Anti-Obesity Prescription Drugs Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Anti-Obesity Prescription Drugs Sales Quantity Share by Application (2018-2024)
Table 40. Global Anti-Obesity Prescription Drugs Sales Quantity Share by Application (2024-2034)
Table 41. Global Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Anti-Obesity Prescription Drugs Revenue Share by Application (2018-2024)
Table 44. Global Anti-Obesity Prescription Drugs Revenue Share by Application (2024-2034)
Table 45. Anti-Obesity Prescription Drugs Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Anti-Obesity Prescription Drugs Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. North America Anti-Obesity Prescription Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Anti-Obesity Prescription Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Anti-Obesity Prescription Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Anti-Obesity Prescription Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Anti-Obesity Prescription Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Anti-Obesity Prescription Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Anti-Obesity Prescription Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Anti-Obesity Prescription Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Anti-Obesity Prescription Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Anti-Obesity Prescription Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Anti-Obesity Prescription Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Anti-Obesity Prescription Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Anti-Obesity Prescription Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Anti-Obesity Prescription Drugs Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Anti-Obesity Prescription Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 117. F Hoffmann La Roche Ltd Company Information
Table 118. F Hoffmann La Roche Ltd Description and Overview
Table 119. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 120. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product and Services
Table 121. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs SWOT Analysis
Table 122. F Hoffmann La Roche Ltd Recent Developments
Table 123. Orexigen Therapeutics Company Information
Table 124. Orexigen Therapeutics Description and Overview
Table 125. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 126. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product and Services
Table 127. Orexigen Therapeutics Anti-Obesity Prescription Drugs SWOT Analysis
Table 128. Orexigen Therapeutics Recent Developments
Table 129. Novo Nordisk A/s Company Information
Table 130. Novo Nordisk A/s Description and Overview
Table 131. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 132. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product and Services
Table 133. Novo Nordisk A/s Anti-Obesity Prescription Drugs SWOT Analysis
Table 134. Novo Nordisk A/s Recent Developments
Table 135. Arena Pharmaceuticals Company Information
Table 136. Arena Pharmaceuticals Description and Overview
Table 137. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 138. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product and Services
Table 139. Arena Pharmaceuticals Anti-Obesity Prescription Drugs SWOT Analysis
Table 140. Arena Pharmaceuticals Recent Developments
Table 141. Glaxosmithkline Company Information
Table 142. Glaxosmithkline Description and Overview
Table 143. Glaxosmithkline Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 144. Glaxosmithkline Anti-Obesity Prescription Drugs Product and Services
Table 145. Glaxosmithkline Anti-Obesity Prescription Drugs SWOT Analysis
Table 146. Glaxosmithkline Recent Developments
Table 147. Vivus Company Information
Table 148. Vivus Description and Overview
Table 149. Vivus Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 150. Vivus Anti-Obesity Prescription Drugs Product and Services
Table 151. Vivus Anti-Obesity Prescription Drugs SWOT Analysis
Table 152. Vivus Recent Developments
Table 153. Boehringer Ingelheim Company Information
Table 154. Boehringer Ingelheim Description and Overview
Table 155. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 156. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product and Services
Table 157. Boehringer Ingelheim Anti-Obesity Prescription Drugs SWOT Analysis
Table 158. Boehringer Ingelheim Recent Developments
Table 159. Alizyme Company Information
Table 160. Alizyme Description and Overview
Table 161. Alizyme Anti-Obesity Prescription Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 162. Alizyme Anti-Obesity Prescription Drugs Product and Services
Table 163. Alizyme Anti-Obesity Prescription Drugs SWOT Analysis
Table 164. Alizyme Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Anti-Obesity Prescription Drugs Distributors List
Table 168. Anti-Obesity Prescription Drugs Customers List
Table 169. Anti-Obesity Prescription Drugs Market Trends
Table 170. Anti-Obesity Prescription Drugs Market Drivers
Table 171. Anti-Obesity Prescription Drugs Market Challenges
Table 172. Anti-Obesity Prescription Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Obesity Prescription Drugs Product Picture
Figure 2. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Anti-Obesity Prescription Drugs Market Share by Type in 2022 & 2034
Figure 4. Pediatric Product Picture
Figure 5. Adult Product Picture
Figure 6. Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Anti-Obesity Prescription Drugs Market Share by Application in 2022 & 2034
Figure 8. Hospitals Pharmacies
Figure 9. Retail Pharmacies
Figure 10. E-commerce
Figure 11. Anti-Obesity Prescription Drugs Report Years Considered
Figure 12. Global Anti-Obesity Prescription Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Anti-Obesity Prescription Drugs Revenue 2018-2034 (US$ Million)
Figure 14. Global Anti-Obesity Prescription Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Anti-Obesity Prescription Drugs Sales Quantity 2018-2034 (K Units)
Figure 16. Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Anti-Obesity Prescription Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Anti-Obesity Prescription Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Anti-Obesity Prescription Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Anti-Obesity Prescription Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Anti-Obesity Prescription Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Anti-Obesity Prescription Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Anti-Obesity Prescription Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Anti-Obesity Prescription Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Anti-Obesity Prescription Drugs Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Anti-Obesity Prescription Drugs Revenue in 2022
Figure 30. Anti-Obesity Prescription Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 33. Global Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 35. North America Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2022
Figure 36. North America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Company in 2022
Figure 37. North America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 39. North America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 41. North America Anti-Obesity Prescription Drugs Revenue Share by Country (2018-2034)
Figure 42. North America Anti-Obesity Prescription Drugs Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Anti-Obesity Prescription Drugs Sales Quantity Market Share by Company in 2022
Figure 46. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2022
Figure 47. Europe Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 49. Europe Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 51. Europe Anti-Obesity Prescription Drugs Revenue Share by Country (2018-2034)
Figure 52. Europe Anti-Obesity Prescription Drugs Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 54. France Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. China Anti-Obesity Prescription Drugs Sales Quantity Market Share by Company in 2022
Figure 59. China Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2022
Figure 60. China Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 62. China Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 64. APAC Anti-Obesity Prescription Drugs Sales Quantity Market Share by Company in 2022
Figure 65. APAC Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2022
Figure 66. APAC Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 68. APAC Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 70. APAC Anti-Obesity Prescription Drugs Revenue Share by Region (2018-2034)
Figure 71. APAC Anti-Obesity Prescription Drugs Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. India Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Obesity Prescription Drugs Revenue Share by Country (2018-2034)
Figure 85. Brazil Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Anti-Obesity Prescription Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Anti-Obesity Prescription Drugs Value Chain
Figure 91. Anti-Obesity Prescription Drugs Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed